The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
OBJECTIVE: To test the validity and sensitivity of the six-item version (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) in treatment-resistant schizophrenia (TRS).
METHOD: Using data from the clozapine phase (2E) of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, we investigated the following: (i) The scalability of PANSS-6 and PANSS-30; (ii) The correlation between PANSS-6 and PANSS-30 total scores; (iii) Whether PANSS-6 could identify cross-sectional symptom remission; and (iv) The efficacy of clozapine, olanzapine, risperidone and quetiapine in TRS using the 'speed of change' on PANSS-6 and PANSS-30 (change in total score per week) as outcome measures.
RESULTS: We found that (i) only PANSS-6 and not PANSS-30 was scalable; (ii) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), (iii) PANSS-6 accurately identified cross-sectional symptom remission as defined by the Andreasen et al. criteria; and (iv) The only antipsychotic that caused improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.50 points/week; 95%CI: -0.84, -0.17) and PANSS-30 (speed of change: -1.41 points/week; 95%CI: -2.80, -0.02) as outcome measures.
CONCLUSION: PANSS-6 validly measures severity, remission and antipsychotic efficacy in TRS.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Acta Psychiatrica Scandinavica |
Vol/bind | 138 |
Udgave nummer | 5 |
Sider (fra-til) | 420-431 |
Antal sider | 12 |
ISSN | 0001-690X |
DOI | |
Status | Udgivet - 2018 |
Bibliografisk note
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
ID: 218437043